

**ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD)**

28 January 2016

### **US PATENT GRANTS FOR IMP731 ANTIBODY**

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”, the “Company”) announces the granting of patent number US 9,244,059 entitled “Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease” by the United States Patent and Trademark Office.

The patent relates to Prima’s IMP731 antibody (originally developed by Immutep). The granted claims provide protection for specific sequences of the antibody and its use in depleting LAG-3<sup>+</sup> T cells by complement dependent cytotoxicity (CDC) and antibody-dependent cell cytotoxicity (ADCC).

Rights for the development of the IMP731 antibody were granted in December 2010 to GSK who have commenced first-in-human clinical trials of a proprietary antibody (GSK2831781) derived from IMP731.

#### **About IMP731 and GSK2831781**

IMP731 and GSK2831781 are designed to specifically deplete potentially pathogenic, recently activated, LAG-3 expressing T cells which are enriched at the disease site in T-cell driven immunoinflammatory disorders and should spare other T-cells which may be necessary for other functions.

Under the terms of the 2010 agreement between Immutep and GSK, GSK has responsibility for all development and associated costs for GSK2831781. Prima BioMed may receive payments and potential milestones totalling up to £64 million and is eligible for single-digit, tiered royalties if all objectives are achieved.

A Phase 1, first-in-human clinical study of GSK2831781 for the treatment of autoimmune diseases has commenced and further information may be obtained at <https://clinicaltrials.gov/ct2/show/NCT02195349>.

#### **About Prima BioMed**

Prima BioMed is a globally active biotechnology company positioned to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.

For personal use only

Prima's current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of the T cell immune response. IMP321, which is a soluble LAG-3Ig fusion protein, is an APC activator boosting T cell responses for cancer chemotherapy and in other combinations which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.

Prima BioMed is listed on the Australian Stock Exchange and on the NASDAQ in the US. For further information please visit [www.primabiomed.com.au](http://www.primabiomed.com.au).

**For further information please contact:**

**U.S. Investors:**

Mr Matthew Beck, The Trout Group LLC  
+1 (646) 378-2933; mbeck@troutgroup.com

**Australia Investor/Media:**

Mr Matthew Gregorowski, Citadel Communications  
+61 (0) 422 534 755; mgregorowski@citadelpr.com.au